StockNews.AI
ELUT
StockNews.AI
180 days

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

1. Q4 and full-year 2024 results release planned for March 6 after market close. 2. Management hosts a live conference call and webcast on March 6 with investor access. 3. Elutia pioneers drug-eluting biomatrix technology for improved implantable device compatibility.

Earnings
+0.63%Current Return
VS
-1.72%S&P 500
$3.202/20 04:16 PM EDTEvent Start
$3.2202/21 10:24 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Earnings schedule announcements tend to have limited immediate impact until actual financials are released; similar past announcements showed minimal pre-announcement price movement.

How important is it?

The upcoming results release is a key catalyst and could trigger significant trading activity once the data comes out, although the announcement itself carries only moderate intrinsic news.

Why Short Term?

Earnings-driven news typically influences the stock in the short term, with volatility occurring post-results announcement.

Related Companies

February 20, 2025 16:05 ET  | Source: Elutia Inc. SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13751810 Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at http://investors.elutia.com/. About ElutiaElutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com. Investors:Matt SteinbergFINN Partnersmatt.steinberg@finnpartners.com

Related News